Intensity Therapeutics begins human testing of intratumoral cancer drug

Intensity Therapeutics said today that the 1st patient was treated in a Phase I/II trial of its intratumorally-administered cancer therapy, INT230-6. The company’s plans to evaluate the safety of its cancer-killing agent in patients with tumors that are treated at the surface of the skin, including breast cancer and melanoma. Intensity Therapeutics also plans to study INT230-6 in patients with deep tumors. Get the full story at our sister site, Drug Delivery Business News. The post Intensity Therapeutics begins human testing of intratumoral cancer drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals intensitytherapeutics Source Type: news

Related Links:

Researchers at Johns Hopkins Medicine have developed a PET imaging technique...Read more on AuntMinnie.comRelated Reading: PET's view of tau could explain women's early dementia PET in the paddock New PET tracer could aid melanoma detection PET tracers help guide breast cancer therapies C-11-based PET tracer could benefit arthritis patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
CONCLUSIONS: With respect to quality of life or reduction of treatment-associated side effects, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer. PMID: 30673872 [PubMed - as supplied by publisher]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
ConclusionsWith respect to quality of life or reduction of treatment-associated side effects, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Our preliminary data demonstrate that ozone therapy is a valid supportive therapy for fatigue in cancer patients, both during cancer therapy and in a palliative setting with no significant side effects. PMID: 30536352 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Researchers at the Stanford University School of Medicine believe a patient-specific stem cell vaccine could become part of mesothelioma treatment — and possibly prevention — in the future. The belief stems from their recent study that demonstrated a consistent immunologic response with genetically-altered stem cells in laboratory mice carrying particular cancer cells. “This could potentially play a role for a large group of — if not all — cancers,” Dr. Joseph Wu, director of the Stanford Cardiovascular Institute, told Asbestos.com. “We envision it potentially being used as a vacci...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study demonstrates the potential of our novel targeted combination therapy delivery vehicle to improve the outcome of cancer treatment. This article is protected by copyright. All rights reserved
Source: Biotechnology and Bioengineering - Category: Biomedical Science Authors: Tags: Article Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Suh SS, Yang EJ, Lee SG, Youn UJ, Han SJ, Kim IC, Kim S Abstract Cancer is the principal cause of human death and occurs through highly complex processes that involve the multiple coordinated mechanisms of tumorigenesis. A number of studies have indicated that the microalgae extracts showed anticancer activity in a variety of human cancer cells and can provide a new insight in the development of novel anti-cancer therapy. Here, in order to investigate molecular mechanisms of anticancer activity in the Antarctic freshwater microalga, Chloromonas sp., we prepared ethanol extract of Chloromonas sp. (ETCH) and...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
In this study we demonstrate the use of clustered regularly interspaced short palindromic repeats (CRISPR)-based epigenome editing to alter cell response to inflammatory environments by repressing inflammatory cytokine cell receptors, specifically TNFR1 and IL1R1. This has applications for many inflammatory-driven diseases. It could be applied for arthritis or to therapeutic cells that are being delivered to inflammatory environments that need to be protected from inflammation." In chronic back pain, for example, slipped or herniated discs are a result of damaged tissue when inflammation causes cells to create ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) are proangiogenic cytokines that sustain tumor angiogenesis and limit antitumor immunity. We show that combined ANGPT2 and VEGFA blockade by a bispecific antibody (A2V) provided superior therapeutic benefits, as compared to the single agents, in both genetically engineered and transplant tumor models, including metastatic breast cancer (MMTV-PyMT), pancreatic neuroendocrine tumor (RIP1-Tag2), and melanoma. Mechanistically, A2V promoted vascular regression, ...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Melanoma | Skin | Skin Cancer | Study